Founder-CEO Dynamics on Venture-Backed Boards
The founder-CEO is a familiar figure in biopharma. The company exists because of a specific scientific insight — a target, a delivery technology, a mechanism — and the person who originated that insight is, in many cases, the same person running the business. The arrangement is so common in early-stage biopharma that boards often treat it as the default rather than as a configuration with its own distinctive governance challenges.
This is a mistake. Founder-CEO companies are not just venture-backed companies that happen to have an unusually committed leader. They are a structurally different governance situation, and the board that does not recognize the difference will find itself struggling with patterns that the standard playbook was not designed to address.
The challenges are not always negative. Many of the strongest biopharma companies in recent history were built by founder-CEOs who carried the scientific vision, the regulatory strategy, and the commercial development through to extraordinary outcomes. The challenges are simply different from those of a board overseeing a professional CEO recruited externally, and the governance posture needs to be different in turn.
This article works through the specific dynamics that arise on founder-CEO boards, where the standard governance assumptions break down, and what an effective board posture actually looks like in this configuration.
What Makes the Founder-CEO Different
The professional CEO recruited from outside arrives at the company with a clear sense of the boundaries between their role and the board's. They were hired by the board, they understand they can be replaced by the board, and the formality of the relationship is established from day one. Their authority comes from their position, and their position is granted by the directors who selected them.
The founder-CEO's authority comes from somewhere else. They built the company. The science is, in many cases, theirs. The early team was recruited by them, often before there was a board to consult. The intellectual property may bear their name on the inventor list. The relationships with key academic collaborators, with the FDA, with the patient community, with the early investors — all of these were built by the founder, and many of them depend on the founder personally rather than on the institution.
This creates a governance asymmetry that does not exist with professional CEOs. The board has the formal authority to oversee the CEO, but the CEO has the substantive standing — scientific, relational, historical — that the company is built on. The asymmetry is not a problem in itself, but it changes how every governance interaction works.
A few practical consequences follow from this. The founder-CEO is harder to evaluate against external benchmarks, because no external benchmark fully captures what they bring. The founder-CEO is harder to coach in conventional ways, because the things a coach might suggest are often things the founder has reasons — sometimes good ones — for doing differently. And the founder-CEO is harder to replace, because the things they uniquely contribute may not be transferable to a successor on any reasonable timeline.
A board that does not understand these consequences will tend to make one of two errors. The first is to treat the founder-CEO as if they were a professional CEO and to apply governance frameworks that do not fit the situation. The second is to treat the founder-CEO as if no governance frameworks apply, and to defer in ways that are not appropriate either. The right posture sits between these two errors, and developing it is one of the more nuanced governance challenges a biopharma board can face.
The Authority Question
The single most consequential governance question on a founder-CEO board is implicit rather than explicit, and it is rarely addressed directly: who is actually in charge?
In a conventional governance arrangement, the answer is straightforward. The board oversees the CEO. The CEO runs the company. The boundary is clear. On founder-CEO boards, the answer is more complicated, because the CEO often holds significant equity (sometimes a controlling or near-controlling position), often has the loyalty of the senior team built around them, and often has the standing with external constituencies that gives them practical authority that is not coextensive with their formal authority.
This creates ambiguity that can be productive when it is well-managed and destructive when it is not. The productive version looks like a founder-CEO who recognizes the legitimacy of board oversight, engages constructively with the board's perspective, and uses their substantive authority to lead the company while accepting governance accountability for the outcomes. The destructive version looks like a founder-CEO who treats board governance as an obstacle to be navigated rather than as a constraint to be respected — running the company as a personal project, providing the board with selective information, and making consequential decisions without genuine board engagement.
Most founder-CEO situations sit somewhere between these extremes, and the board's posture matters significantly in determining which direction the dynamic moves. A board that is consistently engaged, consistently demands honest information flow, and consistently exercises its oversight role in a way that is substantive rather than performative tends to produce founder-CEOs who internalize the legitimacy of governance over time. A board that is passive, deferential, or inconsistent tends to produce the opposite pattern.
The ambiguity is sometimes papered over with formal documents — board resolutions, charter provisions, the company's operating agreement. These documents matter, but they are not what determines the answer in practice. What determines the answer in practice is the cumulative effect of how the board behaves in every meeting and every decision, over a period of years.
The Investor Director Problem in Founder-CEO Companies
In venture-backed biopharma companies, the board typically includes one or more investor directors representing the funds that have led financing rounds. The relationship between these investor directors and the founder-CEO is the single most consequential dynamic on most founder-CEO boards, and it warrants explicit governance attention.
A few patterns recur in this dynamic.
The first is that the investor director and the founder-CEO are often each other's most important counterparties — and yet the relationship is structurally asymmetric in ways that create tension. The investor director represents capital that the company needs. The founder-CEO represents the science and the operational capacity that the investor's capital is funding. The two are mutually dependent in the abstract, but in any given decision — a financing round, a partnership decision, a strategic pivot — the leverage shifts in ways that are not always predictable.
The second pattern is that investor directors have governance obligations that run to multiple constituencies simultaneously. They are fiduciaries to the company and its shareholders generally. They are also accountable to their fund's limited partners, whose interests may not always be perfectly aligned with the company's. And they typically have a portfolio of investments, which means their attention is divided and their judgment is shaped by the patterns they see across other companies — patterns that may or may not apply to the specific situation.
The founder-CEO, in contrast, has a more singular position. The company is, in most cases, their primary professional identity. Their attention is undivided. Their judgment is shaped by deep knowledge of the specific situation rather than by patterns across a portfolio.
The third pattern is that disagreements between investor directors and founder-CEOs tend to escalate in ways that disagreements between independent directors and CEOs do not. The reason is that investor directors have leverage — through their control of future financing, their voting rights on certain decisions, and their relationships with other investors — that independent directors typically do not have. When an investor director and a founder-CEO are genuinely at odds, the dispute can shift the trajectory of the company in ways that go well beyond the specific decision in question.
A well-functioning founder-CEO board has worked out, explicitly or implicitly, how these dynamics will be managed. The best boards have an active board chair or lead director — typically an independent director — who plays a mediating role, who can hold private conversations with both the founder-CEO and the investor director, and who can surface concerns in the board forum in ways that preserve the working relationship between the two principals. Boards that lack this mediating function often find that conflicts escalate faster and resolve worse than they would in a healthier governance environment.
When the Founder Needs to Step Back
One of the most difficult conversations a board can have with a founder-CEO is the conversation about whether the founder remains the right person to be CEO as the company evolves.
The challenge here is structural. The skills that make a founder effective at the earliest stages of a biopharma company — scientific vision, technical depth, willingness to operate with minimal resources, capacity to build conviction in others — are not the same skills that are most important at later stages. The transition from a 10-person preclinical company to a 50-person clinical-stage company involves a different set of leadership demands. The transition from a 50-person company running a Phase II trial to a 200-person company preparing for commercial launch involves another set entirely.
Many founder-CEOs make these transitions successfully. The ability to learn, to delegate, to build infrastructure, to recruit and manage a leadership team — these are learnable skills, and a founder who is genuinely committed to the company's success will often grow into them. But not all founders make the transition, and some founders are better suited to particular stages of the company's evolution than to others.
The board's role here is to maintain an honest assessment of the match between the founder-CEO's capabilities and the company's needs at the current stage, and to surface concerns when the match is becoming strained. This is not the same as forcing a leadership change. It is an ongoing governance conversation about how the founder-CEO's role might evolve as the company evolves — possibly into a permanent CEO position with strengthened operating support, possibly into a Chief Scientific Officer or Executive Chair role with a professional CEO recruited alongside, possibly into something else entirely.
The conversation works best when it is initiated early and treated as a normal aspect of the company's evolution rather than as a crisis. Boards that wait until the founder-CEO is visibly struggling to begin the conversation typically find it much harder than boards that have been having the conversation, in some form, throughout the company's development.
The founder-CEO's response to this conversation is often the most important signal about how the situation will resolve. Founders who engage with the question honestly, who acknowledge that the company's needs may eventually exceed their capacities, and who are willing to consider role evolution as a sign of maturity rather than failure, almost always navigate the transition well — sometimes remaining as CEO for longer than anyone expected, because their willingness to grow is what allowed them to keep growing into the role. Founders who treat the question as an attack, who interpret any discussion of role evolution as a threat to their identity, are sending a different signal. The board that reads that signal correctly will be better prepared for what eventually follows.
What Effective Boards Get Right
The boards that work well in founder-CEO situations tend to share a few characteristics, and they are worth naming explicitly.
They establish, early, a relationship between the founder-CEO and the board that is built on trust rather than on formality. Trust does not mean deference. It means that the founder-CEO believes the board engages with the company's interests in good faith, and that the board believes the founder-CEO provides honest information and engages with governance in good faith. Boards that establish this trust early have it available as a resource when difficult conversations arise. Boards that do not, find that every difficult conversation has to be conducted across a relational deficit that makes everything harder.
They have a strong, active board chair or lead director who is independent of both the founder-CEO and the investor directors, and who has the capacity to mediate when needed. The role of this chair is not to take sides, but to hold the space in which the substantive conversations can happen. This is one of the most underrated governance roles in biopharma, and it is often the variable that distinguishes well-functioning founder-CEO boards from dysfunctional ones.
They invest in the governance relationship itself, not only in the substantive decisions. Board meetings are run well. Information flow is genuine. Executive sessions happen routinely. Individual director check-ins with the CEO are regular. The board chair has private conversations with directors and with the founder-CEO. None of this is glamorous, and none of it appears in any quarterly report. But it is the infrastructure on which good governance in a founder-CEO context depends.
They recognize that the founder-CEO arrangement is a configuration with its own logic, not a deviation from a standard model that needs to be normalized. The best boards do not spend their energy trying to convert the founder-CEO into a professional CEO. They work with the configuration as it is, while maintaining the substantive oversight that any board owes to the company and its stakeholders.
In clinical-stage biopharma, where the gap between scientific insight and successful drug development is so wide that very few companies traverse it, the founder-CEO arrangement remains one of the most productive structures in the industry. The boards that engage with it well — neither over-deferring nor over-formalizing — are the ones that give their companies the best chance of crossing that gap.
Lawrence Fine is CEO of AGCP Farmacêuticos and has direct biopharma board experience through Phase II clinical trials and successful exits.